Erudio Healtherudio.com
Sponsor
Summit Therapeutics trials: what clinicians said in public
HCP commentary reports on 3 clinical trials sponsored by Summit Therapeutics: HARMONi-3, HARMONi-7 and HARMONi-GI3. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 1 more trial with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Summit Therapeutics). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| HARMONi-7 NCT06767514 · Summit Therapeutics | first-line metastatic NSCLC with high PD-L1 expression | Phase 3 | 109 | 43 | Focused | Nov 19, 2026 | Preview |
| HARMONi-3 NCT05899608 · Summit Therapeutics | first-line metastatic non-small cell lung cancer | Phase 3 | 354 | 104 | Deep | Nov 15, 2026 | Preview |
| HARMONi-GI3 NCT07228832 · Summit Therapeutics | first-line metastatic colorectal cancer | Phase 3 | 19 | 10 | Focused | Oct 29, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| HARMONi NCT06396065 · Summit Therapeutics DeepView → | EGFR-mutant advanced non-squamous NSCLC after EGFR-TKI progression | Phase 3 | Deep | View | |||